China, Israel direct resources to imaging AI

China and Israel are global leaders in artificial intelligence (AI) image analysis technology because of government support and industry collaboration, according to a recent Forbes article.

China’s State Council outlined a plan to make domestic AI worth $150 billion by 2030—and the country fell into line. China's largest investment companies have poured money into the endeavor. Tech giant Alibaba took a 25 percent stake in Wanliyun Medical Information Technology to the tune of $35 million. It’s now in the top 10 globally funded medical image analysis AI companies.

One company, Huiying Medical Technology, has partnerships with more than 700 hospitals in China, improving access to data to train AI algorithms.

“Ask any U.S. based medical imaging AI startup the same question, and it would be surprising if the figure reached 100,” wrote Reenita Das of Forbes.

Israel has done surprisingly well for a country of its size, according to the report. The transfer of military advances in computer vision to medical applications is likely one reason. The country also claimed one of the earliest U.S. Food and Drug Administration approved AI algorithms.

Read the entire Forbes story below.

""

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.